Patents by Inventor Richard M. Synenki

Richard M. Synenki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant attenuated clostridium organisms and vaccine
    Patent number: 7972604
    Abstract: The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridium perfringens strain 13, is missing at least nine consecutive amino acid residues including His68. The present invention also discloses attenuated organisms that encode the muteins, as well as the use of such attenuated organisms as vaccines.
    Type: Grant
    Filed: August 27, 2010
    Date of Patent: July 5, 2011
    Assignee: Intervet Inc.
    Inventors: Mark D. Cochran, Gary R. Peterson, Stephen V. Lair, Richard M. Synenki
  • RECOMBINANT ATTENUATED CLOSTRIDIUM ORGANISMS AND VACCINE
    Publication number: 20110008389
    Abstract: The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridium perfringens strain 13, is missing at least nine consecutive amino acid residues including His68. The present invention also discloses attenuated organisms that encode the muteins, as well as the use of such attenuated organisms as vaccines.
    Type: Application
    Filed: August 27, 2010
    Publication date: January 13, 2011
    Applicant: INTERVET INC.
    Inventors: MARK D. COCHRAN, GARY R. PETERSON, STEPHEN V. LAIR, RICHARD M. SYNENKI
  • Recombinant attenuated organisms and vaccine
    Patent number: 7807456
    Abstract: The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridium perfringens strain 13, is missing at least nine consecutive amino acid residues including His68. The present invention also discloses attenuated organisms that encode the muteins, as well as the use of such attenuated organisms as vaccines.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: October 5, 2010
    Assignee: Intervet Inc.
    Inventors: Mark D. Cochran, Gary R. Petersen, Stephen V. Lair, Richard M. Synenki
  • RECOMBINANT ATTENUATED CLOSTRIDIUM ORGANISMS AND VACCINE
    Publication number: 20100166800
    Abstract: The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridium perfringens strain 13, is missing at least nine consecutive amino acid residues including His68. The present invention also discloses attenuated organisms that encode the muteins, as well as the use of such attenuated organisms as vaccines.
    Type: Application
    Filed: December 17, 2009
    Publication date: July 1, 2010
    Inventors: Mark D. Cochran, Gary R. Petersen, Stephen V. Lair, Richard M. Synenki
  • Recombinant attenuated organisms and vaccine
    Patent number: 7732187
    Abstract: The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridium perfringens strain 13, is missing at least nine consecutive amino acid residues including His68. The present invention also discloses attenuated organisms that encode the muteins, as well as the use of such attenuated organisms as vaccines.
    Type: Grant
    Filed: April 12, 2007
    Date of Patent: June 8, 2010
    Assignee: Intervet Inc.
    Inventors: Mark D. Cochran, Gary R. Petersen, Stephen V. Lair, Richard M. Synenki
  • Stable and bioactive modified porcine somatotropin and pharmaceutical compositions thereof
    Patent number: 5849694
    Abstract: The present invention provides a stable and bioactive recombinant small-loop modified somatotropin which has its small-loop cysteines changed to other amino acids or deleted altogether and a method for producing such a small-loop modified somatotropin. Also provided by the present invention are DNA sequences coding for such small-loop modified somatotropins, plasmids containing such sequences, and organisms containing such plasmids. Furthermore, pharmaceutical compositions including small-loop modified somatotropins and methods for using such pharmaceutical compositions are disclosed.
    Type: Grant
    Filed: July 16, 1990
    Date of Patent: December 15, 1998
    Inventors: Richard M. Synenki, Peter M. Rubinelli, Henry E. Auer, James E. Seely